428 related articles for article (PubMed ID: 29242316)
1. Colorectal Cancer Consensus Molecular Subtypes Translated to Preclinical Models Uncover Potentially Targetable Cancer Cell Dependencies.
Sveen A; Bruun J; Eide PW; Eilertsen IA; Ramirez L; Murumägi A; Arjama M; Danielsen SA; Kryeziu K; Elez E; Tabernero J; Guinney J; Palmer HG; Nesbakken A; Kallioniemi O; Dienstmann R; Lothe RA
Clin Cancer Res; 2018 Feb; 24(4):794-806. PubMed ID: 29242316
[No Abstract] [Full Text] [Related]
2. Consensus molecular subtypes of colorectal cancer are recapitulated in in vitro and in vivo models.
Linnekamp JF; Hooff SRV; Prasetyanti PR; Kandimalla R; Buikhuisen JY; Fessler E; Ramesh P; Lee KAST; Bochove GGW; de Jong JH; Cameron K; Leersum RV; Rodermond HM; Franitza M; Nürnberg P; Mangiapane LR; Wang X; Clevers H; Vermeulen L; Stassi G; Medema JP
Cell Death Differ; 2018 Mar; 25(3):616-633. PubMed ID: 29305587
[TBL] [Abstract][Full Text] [Related]
3. Consensus molecular subtype classification of colorectal adenomas.
Komor MA; Bosch LJ; Bounova G; Bolijn AS; Delis-van Diemen PM; Rausch C; Hoogstrate Y; Stubbs AP; de Jong M; Jenster G; van Grieken NC; Carvalho B; Wessels LF; Jimenez CR; Fijneman RJ; Meijer GA;
J Pathol; 2018 Nov; 246(3):266-276. PubMed ID: 29968252
[TBL] [Abstract][Full Text] [Related]
4. CMScaller: an R package for consensus molecular subtyping of colorectal cancer pre-clinical models.
Eide PW; Bruun J; Lothe RA; Sveen A
Sci Rep; 2017 Nov; 7(1):16618. PubMed ID: 29192179
[TBL] [Abstract][Full Text] [Related]
5. A Clinically Applicable Gene-Expression Classifier Reveals Intrinsic and Extrinsic Contributions to Consensus Molecular Subtypes in Primary and Metastatic Colon Cancer.
Piskol R; Huw L; Sergin I; Kljin C; Modrusan Z; Kim D; Kljavin N; Tam R; Patel R; Burton J; Penuel E; Qu X; Koeppen H; Sumiyoshi T; de Sauvage F; Lackner MR; de Sousa E Melo F; Kabbarah O
Clin Cancer Res; 2019 Jul; 25(14):4431-4442. PubMed ID: 31004000
[TBL] [Abstract][Full Text] [Related]
6. The Evolving Role of Consensus Molecular Subtypes: a Step Beyond Inpatient Selection for Treatment of Colorectal Cancer.
Ros J; Baraibar I; Martini G; Salvà F; Saoudi N; Cuadra-Urteaga JL; Dienstmann R; Tabernero J; Élez E
Curr Treat Options Oncol; 2021 Nov; 22(12):113. PubMed ID: 34741675
[TBL] [Abstract][Full Text] [Related]
7. The prognostic impact of consensus molecular subtypes (CMS) and its predictive effects for bevacizumab benefit in metastatic colorectal cancer: molecular analysis of the AGITG MAX clinical trial.
Mooi JK; Wirapati P; Asher R; Lee CK; Savas P; Price TJ; Townsend A; Hardingham J; Buchanan D; Williams D; Tejpar S; Mariadason JM; Tebbutt NC
Ann Oncol; 2018 Nov; 29(11):2240-2246. PubMed ID: 30247524
[TBL] [Abstract][Full Text] [Related]
8. Establishment and characterization of cell lines from chromosomal instable colorectal cancer.
Maletzki C; Gock M; Randow M; Klar E; Huehns M; Prall F; Linnebacher M
World J Gastroenterol; 2015 Jan; 21(1):164-76. PubMed ID: 25574089
[TBL] [Abstract][Full Text] [Related]
9. Immune and Stromal Classification of Colorectal Cancer Is Associated with Molecular Subtypes and Relevant for Precision Immunotherapy.
Becht E; de Reyniès A; Giraldo NA; Pilati C; Buttard B; Lacroix L; Selves J; Sautès-Fridman C; Laurent-Puig P; Fridman WH
Clin Cancer Res; 2016 Aug; 22(16):4057-66. PubMed ID: 26994146
[TBL] [Abstract][Full Text] [Related]
10. Association of Consensus Molecular Subtypes and Molecular Markers With Clinical Outcomes in Patients With Metastatic Colorectal Cancer: Biomarker Analyses From LUME-Colon 1.
Lenz HJ; Argiles G; Yoshino T; Tejpar S; Ciardiello F; Braunger J; Salnikov AV; Gabrielyan O; Schmid R; Höfler J; Kitzing T; Van Cutsem E
Clin Colorectal Cancer; 2021 Mar; 20(1):84-95.e8. PubMed ID: 33041226
[TBL] [Abstract][Full Text] [Related]
11. Prognosis of stage III colorectal carcinomas with FOLFOX adjuvant chemotherapy can be predicted by molecular subtype.
Kwon Y; Park M; Jang M; Yun S; Kim WK; Kim S; Paik S; Lee HJ; Hong S; Kim TI; Min B; Kim H
Oncotarget; 2017 Jun; 8(24):39367-39381. PubMed ID: 28455965
[TBL] [Abstract][Full Text] [Related]
12. Capturing colorectal cancer inter-tumor heterogeneity in patient-derived xenograft (PDX) models.
Prasetyanti PR; van Hooff SR; van Herwaarden T; de Vries N; Kalloe K; Rodermond H; van Leersum R; de Jong JH; Franitza M; Nürnberg P; Todaro M; Stassi G; Medema JP
Int J Cancer; 2019 Jan; 144(2):366-371. PubMed ID: 30151914
[TBL] [Abstract][Full Text] [Related]
13. [Characterization of patients with sporadic colorectal cancer following the new Consensus Molecular Subtypes (CMS)].
Wielandt AM; Villarroel C; Hurtado C; Simian D; Zamorano D; Martínez M; Castro M; Vial MT; Kronberg U; López-Kostner F
Rev Med Chil; 2017 Apr; 145(4):419-430. PubMed ID: 28748988
[TBL] [Abstract][Full Text] [Related]
14. Development and Validation of a Gene Signature Classifier for Consensus Molecular Subtyping of Colorectal Carcinoma in a CLIA-Certified Setting.
Morris JS; Luthra R; Liu Y; Duose DY; Lee W; Reddy NG; Windham J; Chen H; Tong Z; Zhang B; Wei W; Ganiraju M; Broom BM; Alvarez HA; Mejia A; Veeranki O; Routbort MJ; Morris VK; Overman MJ; Menter D; Katkhuda R; Wistuba II; Davis JS; Kopetz S; Maru DM
Clin Cancer Res; 2021 Jan; 27(1):120-130. PubMed ID: 33109741
[TBL] [Abstract][Full Text] [Related]
15. Multi-omics integration identifies a selective vulnerability of colorectal cancer subtypes to YM155.
Zhan T; Faehling V; Rauscher B; Betge J; Ebert MP; Boutros M
Int J Cancer; 2021 Apr; 148(8):1948-1963. PubMed ID: 33186476
[TBL] [Abstract][Full Text] [Related]
16. Classification of patients with metastatic colorectal cancer into consensus molecular subtypes into real-world: A pilot study.
González-Montero J; Burotto M; Valenzuela G; Mateluna D; Buen-Abad F; Toro J; Barajas O; Marcelain K
World J Clin Oncol; 2023 Oct; 14(10):409-419. PubMed ID: 37970108
[TBL] [Abstract][Full Text] [Related]
17. Patient-Derived Xenografts and Matched Cell Lines Identify Pharmacogenomic Vulnerabilities in Colorectal Cancer.
Lazzari L; Corti G; Picco G; Isella C; Montone M; Arcella P; Durinikova E; Zanella ER; Novara L; Barbosa F; Cassingena A; Cancelliere C; Medico E; Sartore-Bianchi A; Siena S; Garnett MJ; Bertotti A; Trusolino L; Di Nicolantonio F; Linnebacher M; Bardelli A; Arena S
Clin Cancer Res; 2019 Oct; 25(20):6243-6259. PubMed ID: 31375513
[TBL] [Abstract][Full Text] [Related]
18. Molecular Subtyping Combined with Biological Pathway Analyses to Study Regorafenib Response in Clinically Relevant Mouse Models of Colorectal Cancer.
Lafferty A; O'Farrell AC; Migliardi G; Khemka N; Lindner AU; Sassi F; Zanella ER; Salvucci M; Vanderheyden E; Modave E; Boeckx B; Halang L; Betge J; Ebert MPA; Dicker P; Argilés G; Tabernero J; Dienstmann R; Medico E; Lambrechts D; Bertotti A; Isella C; Trusolino L; Prehn JHM; Byrne AT
Clin Cancer Res; 2021 Nov; 27(21):5979-5992. PubMed ID: 34426441
[TBL] [Abstract][Full Text] [Related]
19. Multilevel prioritization of gene regulators associated with consensus molecular subtypes of colorectal cancer.
Song K; Cai H; Zheng H; Yang J; Jin L; Xiao H; Zhang J; Zhao Z; Li X; Zhao W; Li X
Brief Bioinform; 2021 Sep; 22(5):. PubMed ID: 33855351
[TBL] [Abstract][Full Text] [Related]
20. Gene expression profiles of CMS2-epithelial/canonical colorectal cancers are largely driven by DNA copy number gains.
Berg KCG; Sveen A; Høland M; Alagaratnam S; Berg M; Danielsen SA; Nesbakken A; Søreide K; Lothe RA
Oncogene; 2019 Aug; 38(33):6109-6122. PubMed ID: 31308487
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
